Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease.
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.
[Multiple sclerosis: new approaches to comprehensive treatment and rehabilitation using the method of reflexology].
Symptom overlap in anxiety and multiple sclerosis.
Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response.
Incidence of Mood or Anxiety Disorders in Children of Parents with Multiple Sclerosis.
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia.
Disability weight for each level of the Expanded Disability Status Scale in multiple sclerosis.
A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C.
Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment.
Cognitive impairment as unusual first manifestation in late-onset relapsing-remitting multiple sclerosis.
Ampyra 10mg beats 5mg, but weak overall results net neutral for ACOR
Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study.
IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases.
Partnering to increase access to community exercise programs for people with stroke, acquired brain injury, and multiple sclerosis.
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Is it time for a new global classification of multiple sclerosis?
Current and future drugs for treatment of MS-associated bladder dysfunction.
Multiple sclerosis: Spinal cord grey matter loss correlates with disability in MS.
Elevated Expression of the Cerebrospinal Fluid Disease Markers Chromogranin A and Clusterin in Astrocytes of Multiple Sclerosis White Matter Lesions.
Unprovoked seizures in multiple sclerosis and systemic lupus erythematosus: A population-based case-control study.
Treatment of facial myokymia in multiple sclerosis with botulinum toxin.
Corpus Callosum Atrophy - A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study.
Acute disseminated encephalomyelitis--a prospective study of clinical profile and in-hospital outcome predictors.
Placebo? no thanks, it might be bad for me!

Pages